Immunotherapeutic Prospects of Infectious Diseases

1. Front Matter

   Pages I-XVIII

   PDF

2. Immunomodulators in Infectious Diseases

   1. Front Matter

      Pages 1-1

      PDF

   2. Immunopharmacology of a Class of Synthetics with Therapeutic Potential in Infections and Other Types of Diseases

      • D. Trizio, A. M. Isetta, G. F. Doria, M. C. Fornasiero, M. Ferrari, R. Ferreccio et al.

      Pages 3-8

   3. Lentinan and its Related Polysaccharides as Host Defence Potentiators: Their Application to Infectious Diseases and Cancer

      • Goro Chihara

      Pages 9-18

   4. Purification and Endotoxin-Like Bioactivities of a Novel Amphiphile from Mycobacterium bovis BCG

      • S. Kotani, A. Nagao, T. Tamura, H. Okamura, A. Nagata, K. Aoyama et al.

      Pages 19-36

   5. Bacterial Surface Components as Immunomodulators

      • W. G. Bessler, B. Kleine, L. Biesert, S. Schlecht, R. Schaude, K-H. Wiesmüller et al.

      Pages 37-48

   6. Effect of Free and Liposome-Encapsulated MTP-PE on Klebsiella pneumoniae Infection in Mice

      • Pernella M. B. Melissen, W. v. Vianen, Y. Rijsbergen, I. A. J. M. Bakker-Woudenberg

      Pages 49-53

   7. Immunomodulatory Capacity of Drugs Evaluated in a Mouse Model of Klebsiella pneumoniae Infection

      • J. Franěk, J. Malina

      Pages 55-58

   8. Modulation of Host Resistance by Polymeric Substances from Baptisia tinctoria and Echinacea purpurea

      • N. Beuscher, K.-H. Scheit, C. Bodinet, D. Egert

      Pages 59-63

   9. Antivirals in Treatment of Experimental Bacterial and Fungal Infections

      • V. B. Dimov, N. D. Ivanovska

      Pages 65-69

   10. Influence of Nonspecific Immunomodulation with Thymic Preparations on the Result of Infection in some Experimental Parasitoses

       • J. Heřmánek, B. Koudela

       Pages 71-75

   11. In Vitro Influence of Bovine and Human Diacetyl-Splenopentin on Human Peripheral Blood Lymphocytes in Comparison to Thymopentin

       • H.-U. Simon, I.-J. Körner, W.-D. Döcke, K. Forner, H.-D. Volk

       Pages 77-81

   12. Some Novel Pharmacological Properties of Lentinan

       • K. Mašek, H. Mostecká, J. Seifert, H. Farghali, G. Chihara, Y. Kaneko

       Pages 83-87

3. AIDS

   1. Front Matter

      Pages 89-89

      PDF

   2. Status and Current Prospects for the Immunotherapy of Human Immunodeficiency Virus (HIV) Infection

      • John W. Hadden

      Pages 91-107

   3. Biological Actions of Polysaccharides and Those Derivatives Against Cancer and AIDS

      • Y. Kaneko, Y. Yamamoto, T. Uryu

      Pages 109-119

   4. Experience with IMREG-1, a Leukocyte Derived Immunomodulator on Candidiasis and Progression of Disease in Patients with AIDS-Related Complex

      • A. Arthur Gottlieb, Marise S. Gottlieb

      Pages 121-128

   5. Reduced Replication of Human Immunodeficiency Virus in Promonocytic Cells by Bacterial Immunomodulators and Anti-Retroviral Drugs at an Early Stage of HIV-Infection

      • Beate Rohde-Schulz, K. N. Masihi, W. Lange

      Pages 129-133

   6. Abrogation of Azidothymidine-Induced Bone Marrow Toxicity by Free and Liposomal Muramyl Dipeptide

      • N. C. Phillips, C. Tsoukas, L. Chedid

      Pages 135-139

   7. Effectiveness of Diethyldithiocarbamate (DTC, Imuthiol) in Reducing the Incidence of Opportunistic Infections in Patients with AIDS and ARC. A Randomized Placebo Controlled Multicenter Study

      • E. M. Hersh, J. Caraux, L. Hessel, US Imuthiol AIDS Group

      Pages 141-142

The prevention and control of infectious diseases represents, even today, an important public health problem for responsible national and international authorities. Newly emerging p.athogens such as human immunodeficiency virus (HIV) , legionella, and bovine spongiform encephalopathy (BSE) have captured current public awareness. Despite significant success against smallpox, polio­ myelitis, mumps, and measles, the vast majority of infectious diseases are yet to be satisfactorily controlled. Limited efficacy of some vaccines, e. g., against influenza viruses, or their nonavailability have hampered an effective control of many infections. A meaningful reduction of the health risks posed by microbial pathogens is of crucial importance. Increased efforts need to be exerted in areas of active and passive immunization as well as in stimulation of enhanced nonspecific resistance .. Progress in the field of infectious diseases can be accelerated when a generation of new improved vaccines are developed. These vaccines should be capable of activat­ ing the cellular and the humoral immune responses as well as inducing persistent immunological memory. Development of novel regimens for enhancing natural resistance against infections is also progressively gaining in importance. The urgency increases as chemotherapy against viral and other infections further continues to be plagued by a carousel of a limited number of licensed drugs, problems of side effects, and development of drug resistance. It is becoming expedient that future strategies embrace a policy directed towards triggering mechanisms capable of inducing specific and nonspecific host defences.

• AIDS
• Parasitic Infections
• bacteria
• cytokine
• diseases
• immunomodulation
• infection
• infections
• infectious
• infectious disease
• infectious diseases
• parasite
• resistance
• vaccination
• vaccine

• Robert-Koch-Institut, Bundesgesundheitsamtes, Berlin 65, Germany

  K. Noel Masihi, Werner Lange

Policies and ethics